Oncology

Latest News

AJMC Q&A with Eileen Peng, PharmD | Background image credit: ipopba - stock.adobe.com

The Role of Pharmacists Expands Beyond Dispensing for Novel Cancer Therapies: Eileen Peng, PharmD

By Laura Joszt, MA
Eileen Peng, PharmD

May 21st 2025

The advent of novel cancer care therapies such as chimeric antigen receptor T-cell therapy and bispecific antibodies is transforming the role of pharmacists in enhancing patient care.

Future validation studies with a larger sample size are warranted to ensure the technique will be useful in a clinical setting. | Image credit: Artur Wnorowski - stock.adobe.com

Novel, Noninvasive Skin Cancer Detection Method Shows Promise

By Jared Kaltwasser

May 18th 2025

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

By Pearl Steinzor

May 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

October 24th 2012

Change to FIT Increased CRC Screening Rates: Evaluation of a US Screening Outreach Program

Elizabeth G. Liles, MD, MSCR Nancy Perrin, PhD Ana Gabriela Rosales, MS Adrianne C. Feldstein, MD, MS David H. Smith, RPh, MHA, PhD David M. Mosen, PhD, MPH Jennifer L. Schneider, MPH

Fecal immunochemical testing resulted in higher colorectal cancer screening rates than did guaiac fecal occult blood tests, with less dependence on office visits.

Aimee Tharaldson, PharmD, Identifies Trends in the Specialty Pharmacy Market

October 11th 2012

Aimee Tharaldson, PharmD, Identifies Trends in the Specialty Pharmacy Market

In this video, Aimee Tharaldson, PharmD, discusses some of the current trends in the specialty pharmacy market. In addition, Dr. Tharaldson specifically comments on the oncology pipeline, which currently has the most activity.

October 11th 2012

Therapeutic Vaccine Shows Potential in Fighting Cervical Cancer

October 10th 2012

3-D Mammograms Offer a New Option for Breast Cancer Screening

October 5th 2012

The Evolving Role of the Pharmacist in Oncology Care

The role of the pharmacist in the care of patients with cancer is evolving. Pharmacists can help optimize treatment outcomes for each patient through use of patient-specific and disease-specific strategies.

October 3rd 2012

Cancer Treatment Speeded by Genome Superhighway: Creator

October 3rd 2012

Prostate-Cancer Test May Reduce Repeat Biopsies: Study

October 1st 2012

Roche's Breast Cancer Franchise Boosted by Trial Data

September 27th 2012

Five-Cent Diabetes Pill From 1958 May Be New Cancer Drug

September 20th 2012

Crizotinib Active in ALK-Positive Pediatric Cancer

September 20th 2012

Oncology Leaders Praise Health Law Ruling-With Caveats

Beth Fand Incollingo

September 20th 2012

State-Level Projections of Cancer-Related Medical Care Costs: 2010 to 2020

Justin G. Trogdon, PhD Florence K. L. Tangka, PhD Donatus U. Ekwueme, PhD Gery P. Guy Jr, PhD Isaac Nwaise, PhD Diane Orenstein, PhD

State-level estimates of the number of people treated for cancer and the average cost of their treatment by state from 2010 through 2020.

September 20th 2012

How Can We Get Better Value in End-of-Life Care?

Stanton R. Mehr

September 20th 2012

Down the Road for Breast Cancer

Michael Marlan Mohundro, PharmD Brice Labruzzo Mohundro, PharmD

Targeted Therapies to Further Improve Outcomes

September 20th 2012

How Payers and Oncologists Really Feel About Oncology Pathways

Kim Farina, PhD

September 20th 2012

Partnering With a Payer to Develop a Value-Based Medical Home Pilot: A West Coast Practice's Experience

Linda D. Bosserman, MD, FACP Diana Verrilli Wendy McNatt

September 20th 2012

Oncology Patient-Centered Medical Home

John D. Sprandio, MD, FACP

September 20th 2012

Medical Drug Benefit Management in the Pathway Era

Kim Farina, PhD

September 19th 2012

Outpatient-Shopping Behavior and Survival Rates in Newly Diagnosed Cancer Patients

Shang-Jyh Chiou, DrPH Shiow-Ing Wang, PhD Chien-Hsiang Liu, PhD Chih-Liang Yaung, PhD

Higher incomes, higher comorbidity scores, and more advanced cancer were associated with outpatient-shopping behavior in Taiwanese patients.

September 18th 2012

Implementation of Cancer Clinical Care Pathways

Bruce A. Feinberg, DO James Lang, PharmD, MBA James Grzegorczyk, MS, RPh Donna Stark, RPh, MBA Thomas Rybarczyk, RN, BSN Thomas Leyden, MBA Joseph Cooper Thomas Ruane, MD Scott Milligan, PhD

September 18th 2012

Trends in the 2012 Eisai Oncology Digest: Counseling and Communication of Cancer Treatment

September 18th 2012

The Keys to Obtaining Best Value in Non-Small Cell Lung Cancer

Marj P. Zimmerman, MS, BSPharm, RPh Stanton R. Mehr

September 17th 2012

Achieving Quality and Containing Cost Through Oncology Pharmacy Management

Kim Farina, PhD

September 17th 2012

Treatment and Cost Implications of Pertuzumab

Michael E. Chernew, PhD; Lee N. Newcomer, MD, MHA; and Sandra M. Swain, MD; examine the treatment benefits, cost concerns, and insurance coverage strategies for pertuzumab.

August 17th 2012

Trends in the 2012 Eisai Oncology Digest: Counseling and Communication of Cancer Treatment

This article was sponsored by Eisai Inc. The 2012 Eisai Oncology Digest was commissioned funded by Eisai Inc.

Mark Zitter, MBA, Discusses Oncology Pathways

August 7th 2012

Mark Zitter, MBA, Discusses Oncology Pathways

Mark Zitter, MBA, CEO of the Zitter Group, states that oncology pathways can standardize the way care is delivered while improving quality and reducing costs.

August 3rd 2012

Sanofi, Regeneron Win U.S. Approval for Cancer Medicine

July 20th 2012

How Fake Cancer Drugs Entered U.S.

July 18th 2012

COA Oncology Medical Home Committee Approves 16 Measures To Evaluate And Reward Quality, Cost Efficiency And Outcomes

July 12th 2012

Automated Phone and Mail Population Outreach to Promote Colorectal Cancer Screening

Karin L. Kempe, MD, MPH Susan M. Shetterly, MS Eric K. France, MD, MSPH Theodore R. Levin, MD

Automated phone and mail population outreach resulted in an almost 4-fold increase in the rate of screening for colorectal cancer even without an office visit.

...

175 176 177 178 179 180 181 182 183

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions